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’ INTRODUCTION
Neuropeptides are expressed as signaling molecules in all
animal groups which possess a nervous system.1,2 The sequences
of neuropeptides are determined by genes and highly conserved
across species. Neuropeptides play signaling roles in both
nervous and endocrine systems and thus are involved in diverse
physiological processes such as mood, sleep, pain, reward, and
social behaviors.1,36 Comprehensive characterization of neuro-
peptides in various species is essential to provide the fundamental
understanding of neuropeptide function in basic neuroscience,
pharmaceutical, and/or clinical research.
MS has become the method of choice for determining
the exact sequence, including post-translational modiﬁcations
(PTMs) of peptides and proteins from complex biological
samples.7,8 Compared to traditional techniques such as immuno-
cytochemistry,9MS-based neuropeptidomic studies permit faster
and more speciﬁc structural identiﬁcation.6,1016 The character-
ization of endogenous neuropeptides in animal models such as
mice and rats has provided a wealth of information about
signaling molecules in the nervous and endocrine systems.14,17
Until now, the most commonly used neuropeptidomics strate-
gies identify neuropeptides by using data-dependent LCMS/
MS analysis, where parent mass selection is usually determined
solely according to the abundances of respective peptides,
without considering their biological properties. This can result
in low identiﬁcation rates for neuropeptides, because many of
them are present in the brain at low concentrations and are
thus rarely selected for fragmentation. Neuropeptide identiﬁ-
cation also depends critically on the quality of MS and MS/MS
spectra of a single sequence.1821 Thus, it remains challenging
in neuropeptidomics to conﬁrm the sequences of neuropep-
tides that have low fragmentation informationMS/MS spectra.
This is particularly true when using the common collision-
induced dissociation (CID) mode, where many neuropeptides
with long sequences exhibit irregular fragmentation patterns
and therefore cannot be identiﬁed with high conﬁdence.22
Additional information is therefore required to overcome these
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ABSTRACT: Neuropeptidomics is used to characterize endogenous
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ysis, database construction, de novo sequencing, precursor protein search, and homology analysis. Using this integrated approach,
we identiﬁed 107 endogenous peptides that have sequences identical or similar to those from other mammalian species. High
accuracy MS and tandem MS information, with BLAST analysis and chromatographic characteristics were used to conﬁrm the
sequences of all the identiﬁed peptides. Interestingly, further sequence homology analysis demonstrated that tree shrew peptides
have a signiﬁcantly higher degree of homology to equivalent sequences in humans than those in mice or rats, consistent with the
close phylogenetic relationship between tree shrews and primates. Our results provide the ﬁrst extensive characterization of the
peptidome in tree shrews, which now permits characterization of their function in nervous and endocrine system. As the approach
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limitations, for example, knowledge about highly conserved struc-
tural motifs or chromatographic characteristics of known peptides.
Our present study targets neuropeptides from tree shrews and
aims to provide an in-depth neuropeptidomics investigation.
Tree shrews are small animals that are similar in size to rats but
phylogenetically very close to primates.23,24 Neuropeptidomic
research on an animal model such as the tree shrew is challenging
because complete proteome information is not yet available.
Therefore, a sequence search on its own protein databases, as
commonly done for mice and rats, cannot be performed in this
species. This complicates the comprehensive characterization of
neuropeptides in the tree shrew. However, due to the highly
conserved nature of neuropeptides,2 we can predict that not all,
but a large number of neuropeptides in tree shrews will have
sequences identical to those in related mammalian species. Many
of the other neuropeptides may have highly similar structures to
their sequence equivalents, with only a small fraction of amino
acid substitutions. Therefore, a MS-based approach that is
capable of integrating known structural characteristics of neuro-
peptides will allow the identiﬁcation of many endogenous tree
shrew peptides in a fast and eﬃcient manner.
Fully using the advantages of MS together with known
properties of neuropeptides, we developed an integrated MS-
based approach to characterize neuropeptides in tree shrews.
The data acquisition was conducted by combining (i) data-
dependent, (ii) directed, and (iii) targeted LCFT-MS/MS
analysis. We thus take advantage of recent developments in
proteomics, which have demonstrated that the use of directed or
targeted LCMS/MS is able to improve detection capability and
identiﬁcation eﬃciency for peptides by rearrangement of parent
ion selections.25,26 We used a directed LCMS/MS analysis,
conducted according to the results of a data-dependent analysis,
while the targeted LCFT-MS/MS analysis was undertaken
using parent ion lists of neuropeptides or fragments that were
reported in the literature for other mammalian species. All the
MS information was then subjected to de novo sequencing-based
hybrid spectral analysis.27,28 To identify the peptides that have
low information content MS/MS spectra, we used truncated
peptides and/or chromatographic characteristics to correct and
conﬁrm their sequences. Using our integrated approach, a large
number of neuropeptides that have sequences identical or
homologous to those in any other species were identiﬁed with
high conﬁdence from tree shrews.
’EXPERIMENTAL SECTION
Materials
LCMS grade acetonitrile and formic acid were purchased
from Fisher Scientiﬁc (New Jersey, USA) and Fluka (Wisconsin,
USA), respectively. Acetic acid was purchased from Fluka
(Buchs, Switzerland). Pure water was prepared by GenPure
system (TKA, Niederelbert, Germany). Siliconized microcentri-
fuge tubes (2 mL) were purchased from Eppendorf (Hamburg,
Germany). Microcon centrifugal ﬁlter devices (Vivacon 500)
were purchased from Sartorius AG (Goettingen, Germany
Germany).
Animals
Tree shrews (Tupaia belangeri) were used in experiments
(n = 3). All animals were housed under constant temperature and
humidity with free access to food and water. All procedures with
live animals were conducted with protocols approved by the
veterinary oﬃce of Fribourg, Switzerland.
Sample Preparation
To reduce the interference peptides produced from fragmen-
tation of proteins,14 restricted temperature control was used to
minimize the degeneration of the endogenous neuropeptides.
Two male tree shrews of six years old were sacriﬁced by
decapitation after anesthetized with ketamine (100 mg/kg,
Streuli Pharma AG, Uznach, Switzerland), then the brains were
heat stabilized by using Denator irradiation (Denator AB,
Gothenburg, Sweden) as described elsewhere.29 The left and
right striatum were dissected from the denaturized brain.
Neuropeptides were extracted three times from each striatum.
The three-step extraction was conducted using a gradient of
diﬀerent methanol solutions: (i) 10% methanol containing 0.2%
formic acid, (ii) 30% methanol containing 0.2% formic acid, and
(iii) 50% methanol containing 0.2% formic acid, respectively. In
each extraction step, 5 μL of solution was used per 1 mg of tissue,
and the sample was homogenized twice (each time 20 s) within
1 min by a Precellys 24 homogenizer (Bertin Technologies,
Montigny-le-Bretonneux, France). After homogenization, the
sample was centrifuged at 22000g for 60 min at 4 C. All
supernatants obtained from the three step extractions were
mixed and ﬁltered on a 10 kDa cutoﬀ ﬁlter (Vivacon 500,
Sartorius AG, Goettingen, Germany) by centrifuging for 90 min
at 14000g at 4 C. The usage of organic solvent in samples was
demonstrated to be necessary to increase the recovery of large
peptides in injection, separation, and storage.30,31 The cal-
culated content of methanol in the ﬁnal sample solution was 30%.
FT-MS Data Acquisition
The peptide extracts from the tree shrew brain were analyzed
using a LTQ-Orbitrap Discovery (Thermo Fisher Scientiﬁc,
Bremen, Germany) coupled to a 2D NanoLC (Eksigent Tech-
nologies, USA). In a LCMS analysis, the extract was repeatedly
injected 5 times (5 μL/times) with a 1D pump (Chanel 1) to a
trap column (100 μm ID, 2 cm long), which was packed with a
ReproSil-Pur C18 AQ particles (5 μm, 100 Å; Dr. Maisch
GmbH, Ammerbuch-Entringen, Germany) in a peek column
holder (Upchurch, Oak Harbor, USA). The interval between
each two injections was 3 min. The trap column was kept eluting
with 2% acetonitrile and 98% water containing 0.2% formic acid.
The elution direction of the trap column was reversed through a
10-port valve when it was switched to couple with the analytical
column. The analytical column used C18 AQ (3 μm, 100 Å; Dr.
Maisch GmbH) as medium which was packed in a Picofrit
capillary with an emitter tip of 10 μm (NewObjective, Cam-
bridge, USA). The mobile phase A and B in 2D pump (Chanel 2)
were 0.2% formic acid and 95% acetonitrile containing 0.2%
formic acid, respectively. The mobile phases were eluted on
the analytical column at 300 nL/min with a gradient proﬁle as
06 min, 2% B; 612 min, 220% B; 1280 min, 2050% B;
8085 min, 5060% B; 8590 min, 6095% B; and 90
100 min, 95% B.
Data acquisition on the LTQ-FTMS instrument consisted of a
full FTMS scan event at amass range of 3502000m/z.The lock
mass (445.120025 from polydimethylcyclosiloxane) was used for
real time internal recalibration.32 The mass resolution for each
scan event was kept at 30 000. The ﬁrst and ﬁfth most intensive
ions were selected and fragmented using CID. Dynamic exclu-
sion was set as a repeat count of 1, exclusion duration of 180 s,
and a repeat duration of 30 s. OtherMS/MS parameters were set:
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isolation width, m/z 2; normalized collision energy, 30%; activa-
tion Q, 0.25; and activation time, 50 ms.
The peptides in tree shrew brain extracts were analyzed using
three methods which included data-dependent acquisition
(DDA), directed and targeted LCFT-MS/MS. The brain
samples were ﬁrst analyzed using DDA-LCFT-MS/MS. Then
the samples were analyzed using directed LCFT-MS/MS as
described elsewhere.26 In brief, the m/z of peptides in the DDA-
LCFT-MS/MS data were examined with the software (Sieve,
1.2 version, Thermo, CA, USA) and ﬁltered using charge states
and intensities. The MS1 signals were determined with the
following parameters: mass range of 0.02 Da, intensity threshold
of minimal 100 000. The features with charge states ranging from
2 to 5 were collected in the inclusion mass list of tree shrew
features for the directed LCMS/MS analysis. In the targeted
LCMS/MS analysis, the inclusion lists of neuropeptides were
collected from the neuropeptidomic studies conducted on
mice,17,19 rats,11,33,34 and humans,35,36 respectively. The parent
mass lists were loaded to the FT-MS/MS scan for selective frag-
mentation the target peptides. To acquire high quality MS/MS
information, 500750 ms maximum injection time was used in
FT-MS/MS scan.
Spectral Interpretation
All the raw LCFT-MS/MS data were subjected to Peaks
Studio 5.2 (BSI, Canada) for spectral interpretation.27 Peaks
Studio 5.2 is composed of functions such as Data Reﬁnement,
Auto De Novo, Peaks Search, and Spider (homology search).37
The Data Reﬁnement program allows correcting of the parent
mass and charge states to provide accurate monoisotopic mass of
a peptide. The scans of quality value > 0.3 were kept for further
sequence analysis. Data processing, including peak centroiding,
charge deconvolution, and deisotope, was conducted for data
reﬁnement.
The reﬁned data were subjected to AutoDeNovo program for
sequencing with the mass tolerance of parent ions and product
ions set at 10 ppm and 0.05 Da, respectively. No enzyme
was speciﬁed for cleavage. Variable PTMs, including, amidation
(C-terminal), acetylation (N-terminal), pyroglutamalytion from
glutamatic acid, and glutamine (N-terminal) were selected in de
novo sequencing.
De novo sequencing-based protein ID search was used to
sequence tree shrew peptides that are identical to those
from other species. The database search was conducted on
a customized database constructed using predicted peptides
from species in Euarchontoglires using a method described else-
where.19 Brieﬂy, the database was made with predicted neuro-
peptides of known precursors from Euarchontoglires species
(50 377 entries). The cleavage is made according to the following
template: (K/R)Xm(K/R) Xk (K/R)Xn(K/R) where X is any
amino acid, K is lysine and R is arginine, and m and n correspond
to 0, 2, 4, 6, and k corresponds to 350 amino acids. The residues
Xk represent the predicted neuropeptide sequence.18,38 The
database search was ﬁrst performed for peptides with +1, +2,
and +3 charge states using the mass tolerance of parent ions and
product ions set at 10 ppm and 0.05 Da, respectively. Then the
search was performed for peptides withg+4 charge states using
the mass tolerance of parent ions and product ions set at 10
ppm and 2Da, respectively. Estimation of false positives was con-
ducted by searching all spectra against decoy databases. The
cutoﬀp-value forpeptide identiﬁcation inPeaks searchwas<1 103.
Homology search (mass tolerance 0.5Da) was used toﬁnd candidates
of peptides that have a high degree of homology to those from other
species. The homology search was conducted on the de novo
sequencing results using the same PTMs as used in Auto De Novo
program.
To conﬁrm sequences identiﬁed from the database search, all
the search results were subjected to manual inspection. A
sequence was considered correct only if they match all the
following criteria: (1) the mass of a peptide must have been
calculated from the monoisotopic ions of a peptide; (2) all the
database search results were inspected with de novo sequencing
results; (3) the peptide mass had to be within 10 ppm of the
theoretical mass; (4) for peptides with +1, +2, and +3 charge
states, the major fragments observed in MS/MS have to match
within 0.05 Da to predicted monoisotopic fragmentation ions.
For peptides withg+4 charge states, 1 or 2 Da shift is allowed to
inspect the major fragments according to their predicted mono-
isotopic ions. (5) The fragmentation information must be
enough to recognize the alignment of amino acids, in particular
if they fall in the substitution positions across the adjacent
species.
For comparison of neuropeptides between tree shrews and
mice, the MS/MS data of mouse neuropeptide were searched
using the same parameter as for tree shrew peptides except using
the Swepep database (precursor, 2006-02-15 version).
The predicted fragmentation ions were calculated using the
MS-Product tool in ProteinProsepctor (v.5.7.2, Mass Spectro-
metry Facility, University of California, San Francisco). The
sequence identity analysis was acquired by searching the peptide
sequences in Uniprot. The statistic analysis was conducted with
software Origin 7.5 (OriginLab Corporation, Massachusetts,
US).
BLAST Analysis
The sequence identities of identiﬁed tree shrew peptides
across diﬀerent species were conducted using the BLAST
analysis function in Uniprot. The statistic analysis of identities
(paired t test) was performed with Origin 7.5 (OriginLab Corpora-
tion, Massachusetts, US). For truncated peptides, only the
longest one was counted for acquiring the mean identity of tree
shrew peptides. For example, when both the peptide PPEGVL-
GALLRV and its truncated peptide PPEGVLGALLR are identi-
ﬁed, only the peptide PPEGVLGALLRV is counted to avoid
repeated calculation of the peptide sequence derived from its
neuropeptide precursor protein.
’RESULTS
Combined LCMS/MS Analyses of Tree Shrew Brain
Samples
In the present study, we conducted a neuropeptidomic
analysis of tree shrews by using an integrated approach that
included data-dependent, directed LCMS/MS analysis, and
targeted LCMS/MS analysis. The general workﬂow of the
LCMS/MS analysis methods described in this study is outlined
in Figure 1. The data-dependent LCMS/MS analysis was
conducted with parent ions automatically selected for fragmen-
tation. The subsequent directed LCMS/MS analysis selectively
used the features/peptides acquired in data-dependent LCMS/
MS analysis and removed undesired features/peptides. In the
targeted LCMS/MS analysis, inclusion lists were formed from
collected m/z of reported neuropeptides from mice, rats, and
humans, respectively. All the LCMS/MS data were subsequently
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subjected to de novo sequencing, database search (Protein ID
search) for characterization of peptides that have sequences
identical to those in one or more other species. Meanwhile, the
LCMS/MS data acquired in the ﬁrst and second steps were
used for de novo sequencing-based homology search for char-
acterization of neuropeptides with substituted amino acids in the
sequence. The use of directed and targeted LCMS/MS analysis
allowed the number of identiﬁed neuropeptides to increase
remarkably (from 70 to 107) with limited times of LCMS/
MS analysis.
Identification of Tree Shrew Peptides with Substituted
Amino Acids in Their Sequences
To identify these tree shrew peptides, we used homology
search based on de novo sequencing results. In total we identiﬁed
15 tree shrew peptides with sequences that have amino acid
substitution(s) in comparison to their homologues in other
species (Table 1). Figure 2 represents the spectral identiﬁcation
of a peptide LSDDDRVIWAEQQYQKERS with FT-MS/MS in
high conﬁdence. BLAST analysis showed this peptide has a high
degree of identity to the peptide equivalent of endocrine con-
vertase 1 from mice (89%), rats (89%), and humans (94%),
respectively.
It is worth mentioning that clustering a group of truncated
peptides will assist in prediction, identiﬁcation, and conﬁrmation
of their correct sequences. Truncated peptides are commonly
observed in neuropeptidomics studies, even if strict sample
preparation procedures were used.11,29,3335 Many truncated
peptides detected in neuropeptide analysis were possibly derived
from endogenous proteolytic processing and have their distinct
physiological functions. Because of the overlap in the sequence of
truncated peptides, identiﬁcation of a truncated peptide will
assist in sequencing the original peptide or other truncated
peptides. For example, the peptide LGELFNPYFDPLQWKSSR
had an atypical fragmentation pattern (Supplementary Figure S1,
Supporting Information). It was therefore diﬃcult to identify
the C-terminal sequence. In contrast, a truncated peptide, PYF-
DPLQWKSSRFE, had high-conﬁdent sequence based on the de
novo sequencing results (Supplementary Figure S2, Supporting
Information).With PYFDPLQWKSSRFE identiﬁed, theC-terminal
of the peptide LGELFNPYFDPLQWKSSR was then conﬁrmed.
Further examination of homology search results allowed con-
ﬁrmation of the sequences of another two truncated peptides,
LGELFNPYFDPLQWKSS and LGELFNPYFDPLQWKS. The
same principle fully used the advantage of de novo sequencing
and was therefore applied to other groups of truncated peptides
in this study.
Characterization of Tree Shrew Neuropeptides Identical to
Those in Other Species
Using the de novo sequencing-based protein ID search
function, we characterized 92 peptides that have sequences
identical to those from one or more other species (Table 1).
These peptides included many classical neuropeptides and a
large number of fragment peptides from neuropeptide precur-
sors. These fragment peptides may potentially be biologically
active neuropeptides. This hybrid spectral analysis used the
advantage of the highly accurate FT-MS and FT-MS/MS data
and generated high conﬁdence in identiﬁcation of these peptides,
which allow the majority of the peptide fragment ions assigned,
with a p-value lower than 1  103, a parent mass error of <10
ppm, and a fragment ion mass error of <0.05 Da. Figure 3 depicts
the examples of assignment of FTMS/MS spectra for neuropep-
tide K fragment (124). This peptide has information-rich
tandem MS spectrum. The subsequent de novo sequencing plus
Protein ID search against a customized database allows this
peptide to be identiﬁed in a fast manner with high conﬁdence.
In contrast to peptides that have information-rich tandemMS
spectra, several identiﬁed long neuropeptides, such as neuro-
peptide Y and GAV, have low information content MS/MS
spectra, and thus their sequences are still questionable despite
high database search scores. Homology analysis indicated that
most of these peptides have sequences identical to those in
mice. To further verify the sequence of such peptides, we used
mouse brain samples to examine their structures. Figure 4A
outlines the workﬂow for the sequence veriﬁcation on these
peptides. The extracts from tree shrew brain, mouse brain, and
their mixtures were analyzed using the same LCMS/MS
method. In this case, a tree shrew peptide can be considered as
identical to the mice peptide only if they have the same
chromatographic and mass spectrometric behaviors. Chroma-
tographic and mass spectrometric characteristics are useful
factors to conﬁrm the sequence of peptides, especially with a
high accuracy MS.39 Figure 4B,C represent the process for
conﬁrming the sequence of neuropeptide Y. Neuropeptide Y
has an uneven fragmentation pattern due to the existence of
proline.31 Using high accuracy MS and MS/MS, neuropeptide
Y was identiﬁed by database search based on the high
information content in its N-terminal. The results showed
that tree shrew neuropeptide Y has a fragmentation pattern
highly similar to that of mouse neuropeptide Y (Figure 4B)
with the same parent mass. However, its C-terminal fragmen-
tation spectrum has much less information content, and
importantly the amino acid substitutions of neuropeptide Y
in diﬀerent mammalian species occur in this region. It was
diﬃcult to determine by MS/MS alone whether tree shrew
neuropeptide Y has sequence identical to mouse or human
neuropeptide Y. Further comparative LCMS/MS analysis
demonstrated that neuropeptide Y in tree shrew, mouse samples,
and their mixture had the same chromatographic behavior
(retention time, peak shape) and mass spectrometric properties
(parent mass and fragmentation patterns). On the basis of this
Figure 1. Workﬂow of tree shrew neuropeptide identiﬁcation using
combined LCMS/MS analysis methods. Neuropeptide extracts from
tree shrew brain were analyzed by data-dependent LCMS/MS (1).
Inclusion lists of tree shrew are formed by selectively extracting MS1
peaks from previously acquired LCMS map and subject to the next
round of directed LCMS/MS analysis (2). Meanwhile, the inclusion
lists of other species, including mice, rats, and human, are formed by
collecting m/z of reported neuropeptides. These inclusion lists are
loaded into instrumental methods separately for to further targeted
LCMS/MS analysis (3). De novo-based database (DB) search and
homology search are conducted for LCMS/MS data and ﬁnally
generate a identiﬁcation list of tree shrew peptides.
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information, the sequence of neuropeptide Ywas unambiguously de-
termined. In addition to these classical neuropeptides characterized,
thymosinβ-4 and thymosinβ-10, two peptide hormones that are not
derived from prohormones, were also identiﬁed with this method
(see Supplementary Figures S3 and S4, Supporting Information).
Post translational modiﬁcations (PTMs) were examined dur-
ing peptide identiﬁcation. PTMs have important biological
inﬂuence because they can alter the functional property of
neuropeptides, for example, increase the binding aﬃnity to
receptors or make peptides more resistant to enzymatic
degradation.1 In the present study, we characterized 22 peptides
containing PTMs (see Table 1). Amidation is a PTM that was
identiﬁed with the highest frequency in our spectral interpreta-
tion. C-terminal amidation is speciﬁc to endogenous peptides40
and is required for the functional activation of many neuro-
peptides.41 In all cases where the peptide had a C-terminal amide
group, the precursor contained Gly on the C-terminus; this is
consistent with the known enzymatic reaction that produces
C-terminal amides.42
BLAST Analysis of Tree Shrew Neuropeptides
Peptides as well as neuropeptides in animals will present high
identity when they have close relationship,43 which can be used
to understand their distance in evolution.9 As tree shrews are
speciﬁc animals that are phylogenetically close to primates,23,24 it
can be expected that neuropeptides in tree shrews will show
overall higher homology to primates such as humans than the
homologous neuropeptides in rodents such as mice and rats. To
test this aspect, we determined the mean sequence identity of
tree shrew peptides (96.34 ( 0.96%), rat peptides (92.39 (
1.92%), and mice peptides (91.15 ( 1.98%) to human homo-
logues. Figure 5 shows the diﬀerence between the sequence
identity of the peptides across the four species. Remarkably, the
results showed that the peptides from tree shrew had signiﬁcantly
higher sequence identity to those from humans than from mice
or rats.
’DISCUSSION
Neuropeptides are important signaling molecules that regu-
late diverse physiological processes.1 They have been extensively
characterized in standard laboratory animals such as rats and
Figure 4. Applications of chromatographic and mass spectrometric
information to verify the sequences of unevenly fragmented peptides.
(A) Workﬂow to verify the sequence of neuropeptides that have low
residue assignment. Targeted LCMS/MS analysis are conducted on
three types of neuropeptide samples: extracts of tree shrew brain, mice
brain, and the mixtures of the two extracts (1:1, v/v). T: tree shrew, M:
mouse. The retention time (Rt), parent ions, and fragmentation patterns
are compared to conﬁrm the sequence of unevenly fragmented tree
shrew neuropeptides. (B) The MS/MS spectra and fragmentation ion
assignments of neuropeptide Y from tree shrew andmouse samples. The
C-terminal of tree shrew neuropeptide Y cannot be conﬁrmed, although
its fragmentation pattern in the N-terminal is highly similar to that of
mouse neuropeptide Y. (C) The chromatographic behaviors of neuro-
peptide Y in extracts of tree shrew brain (blue), mice brain (red), and the
mixed extracts of both (green). Neuropeptide Y has very close Rt in the
three types of extracts. Importantly, the fact that no peak split of
neuropeptide Y is observed in the mixed extracts indicate this peptide
has an identical sequence with mouse neuropeptide Y.
Figure 5. Sequence identity analysis of tree shrew, rat and mouse
peptides against their equivalent peptides in human. The values are
represented as mean( SEM. The comparison indicated that tree shrew
peptides have signiﬁcantly higher mean identify to their homologous
peptides in humans than those in mice and rats (paired t test, p < 0.01).
Figure 2. The neuroendocrine convertase 1 fragment LSDDDRVL-
WAEQQYQKERS has been sequenced via homology analysis of the
MS/MS spectrum. The b- (blue) and y-ions (red) are assigned based on
the delta mass diﬀerence between two fragmentation ions. De novo
sequencing plus homology search allows this peptide to be unambigu-
ously identiﬁed. The sequence of this peptide is highly conserved but not
identical to its homologous peptide from mice, rats, and humans.
Figure 3. The neuropeptide K fragment (124) has been sequenced
via analysis of the MS/MS spectrum. The b- (blue) and y-ions (red) are
assigned based on the delta mass diﬀerence between two fragmentation
ions. The sequence of this peptide is identical to that from human or rats
but has one amino acid substitution in mice.
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mice, but to date there has been no systematic investigation in
tree shrews, a small mammal that is a close relative of primates.23,24
We therefore focused on identifying as many neuropeptides as
possible in the tree shrew, which we accomplished by developing
an integrated neuropeptidomics approach. Currently, the tree
shrew genome published online (see NCBI Web site) is still
incomplete and the sequences are mostly unannotated. There-
fore, a BLAST search on this genome can only yield a limited
number of proteins. Thus, the currently available genome
information for tree shrew cannot be used to predict a full list
of neuropeptide precursors for database construction. This
complicates data interpretation and would severely limit the
neuropeptide identiﬁcation rate.19 To circumvent these pro-
blems, we employed several complementary techniques to
identify neuropeptides from tree shrews with high conﬁdence.
The current investigation represents a comprehensive survey of
neuropeptides of the tree shrew using our integrated approach.
Overall, we identiﬁed 107 peptides from 25 neuropeptide pre-
cursors. Of the identiﬁed peptides, some are classical neuropep-
tides, and the others may be potentially bioactive peptides.
Despite the absence of a species-speciﬁc database, our results
are nevertheless comparable, in terms of the total number of pep-
tides identiﬁed, to previous studies using genetic or proteomic
assay-assisted neuropeptidomics.1315,44,45
Our LCMS/MS analysis strategy allowed highly eﬃcient data
acquisition. The analytical strategy combined data-dependent,
directed and targeted LCFT-MS/MS methods for analysis of
tree shrew brain samples. In directed LCMS/MS, the fragmenta-
tion of peptides was conducted using an inclusion list/parent mass
list that was created based on analysis of the data-dependent
LCMS/MS data. The parent ions were selected according to
charge states and intensities of peptides in full scans. This method
allowed the removal redundant signals and consequently increased
the peptide identiﬁcation eﬃciency.26 Meanwhile, the targeted
LCMS/MS analysis allowed the screening of neuropeptides
based on the prediction that a large number of tree shrew
neuropeptides might be identical to their counterparts in one or
more other mammals. To increase the probability of ﬁnding a
peptide with identical sequence in the database, we created
inclusion lists from four other species, in this study, from mice,
rats, and humans. Current neuropeptidomic data were collected in
these species using LCESI-MS/MS. The reported m/z and
charge states of parent ions would therefore be the preferred states
of peptides in ESI mode, which we used in our analysis. The
creation of such inclusion lists is helpful to ﬁnd neuropeptides, if
they exist in the samples even at low concentrations. Additionally,
when a low number of peptides were selected for fragmentation,
some important CID parameters, such as maximum accumulation
time, could be specially optimized to acquire high quality MS/MS
spectra of all targeted peptides. Our targeted LCMS/MS analysis
is thus especially useful for detecting peptides with low abundance
signals. Because of the high eﬃciency, directed/targeted LCMS/
MS are suited for very small quantities, such as those that can be
obtained from brain tissue samples. Importantly, this method can
also fully use the advantages of FT-MS/MS, because the application
of FT-MS/MSwas able to increase the conﬁdence of sequencing,46
but FT-MS/MS has lower sensitivity and slower scan speed than
low resolution MS/MS conducted in other detectors such as ion
traps.32Using directed and targeted LCMS/MS analysis, wewere
indeed able to identify a higher number of peptides, in total about
50% more, compared to our standard method of data-dependent
LCMS/MS analysis.
During evolution, the majority of neuropeptides have been
highly conserved across species, with identical sequences occur-
ring often across related species. On the basis of this principle, we
conducted direct protein search and homology search to allow
rapid identiﬁcation of tree shrew peptides. Subsequently, we used
combinational methods to verify the sequence of each neuro-
peptide. The validation of neuropeptidomic results remains
challenging.22 Although high accuracy measurement of both
parent mass and fragment mass signiﬁcantly narrows the limits in
database searching and increases the capability in the discovery of
peptides,30,46 it sometimes fails to determine the full peptide
sequence. This can happen especially for peptides with low
information content MS/MS spectra. Prior knowledge of struc-
tural other peptide characteristics can support the validation of
peptide sequence in such cases. Accordingly, we used the
sequence and the retention time of mouse neuropeptides to
validate the sequences of several tree shrew neuropeptides in
question, for example, the long neuropeptides neuropeptide Y
and GAV. Our results demonstrate that high accuracy mass
spectrometric measurement plus a retention time criterion can
be an eﬃcient way of peptide identiﬁcation, which is consistent
with the previous observations in proteomic studies.39
Tree shrews are interesting animal models used in brain
research. Our study demonstrated that tree shrew peptides have
a signiﬁcantly higher degree of homology to equivalent se-
quences in humans than those in mice or rats, consistent with
the close phylogenetic relationship between tree shrews and pri-
mates.23,24 As animal models, tree shrews thus provide a sig-
niﬁcantly closer approximation to humans in terms of biological
signaling mechanisms than the standard laboratory animals such
as rats and mice.
’CONCLUSION
We present an integrated approach for the comprehensive
characterization of neuropeptides in tree shrews. This approach
exploits the high degree of conservation of neuropeptides across
mammalian species and fully uses the advantages of directed and
targeted LCFT-MS/MS. Our study provides a complete over-
view of tree shrew neuropeptides, some of which are novel and
most of which have not been functionally studied in tree shrews
to date. Our ﬁnding now permits deep characterization of their
function in the nervous and endocrine system of tree shrews in
diverse biological studies.
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